Oxaloacetate

Oxaloacetate

SCHEMBL898612

O=C(O)CC(=O)C(=O)O.O=C(O)CC(=O)C(=O)O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.57
SRR Q9GZT4 1/20 0.57
OR51E2 Q9H255 3/20 0.50
EGLN1 Q9GZT9 2/20 0.50
MAPK1 P28482 1/20 0.50
SLC13A3 Q8WWT9 1/20 0.50
FEN1 P39748 4/20 0.42
ERCC5 P28715 3/20 0.42
PTPN1 P18031 1/20 0.42
TSHR P16473 3/20 0.41
KDM4E B2RXH2 1/20 0.41
HAO1 Q9UJM8 3/20 0.39
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
FFAR3 O14843 1/20 0.35
GLRA1 P23415 1/20 0.35
SLC6A9 P48067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxaloacetate SCHEMBL4298763 1.00 LDHA (0.57) LDHASRROR51E2EGLN1MAPK1
Oxaloacetate SCHEMBL8464 1.00
Oxaloacetate SCHEMBL6545252 0.96 LDHA (0.53) LDHASRROR51E2EGLN1MAPK1
Oxaloacetate SCHEMBL20912993 0.96 LDHA (0.53) LDHASRROR51E2EGLN1MAPK1
Oxaloacetate SCHEMBL9994505 0.96 LDHA (0.53) LDHASRROR51E2EGLN1MAPK1
Oxaloacetate SCHEMBL25210523 0.96
Oxaloacetate SCHEMBL6545256 0.96 LDHA (0.53) LDHASRROR51E2EGLN1MAPK1
Oxaloacetate SCHEMBL9782818 0.96 LDHA (0.53) LDHASRROR51E2EGLN1MAPK1
Oxaloacetate SCHEMBL11328361 0.96 LDHA (0.53) LDHASRROR51E2EGLN1MAPK1
Oxaloacetate SCHEMBL8638879 0.96 LDHA (0.53) LDHASRROR51E2EGLN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250262177-A1 METHOD TO ALLEVIATE THE SYMPTOMS OF PMS CASH ALAN B (US) 2025-08-21 US disclosed
US-12324794-B2 Method to alleviate the symptoms of PMS CASH ALAN B (US) 2025-06-10 US disclosed
US-20250079000-A1 METHODS AND MARKERS FOR DIAGNOSIS OF PARKINSON'S DISEASE BERG SURVIVOR’S TRUST 2025-03-06 US disclosed
US-20240115529-A1 METHOD TO ALLEVIATE THE SYMPTOMS OF PMS CASH ALAN B (US) 2024-04-11 US disclosed
US-11865092-B2 Method to alleviate the symptoms of PMS CASH, ALAN B. 2024-01-09 US disclosed
EP-3515428-B1 METHOD TO ALLEVIATE THE SYMPTOMS OF PMS CASH ALAN B (US) 2023-06-07 EP disclosed
WO-2022241292-A2 USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PARKINSON'S DISEASE BERG LLC (US) 2022-11-17 WO disclosed
CN-110382685-A For improving the biology and method of the expression plum surprise yeast xylose transport albumen of xylose absorption 创新生物科学公司 2019-10-25 CN disclosed
CN-110325640-A Plum surprise yeast kind for compound biosynthesis 创新生物科学公司 2019-10-11 CN disclosed
CN-104718292-B The microorganism of carbon dioxide fixation circulation is imported 三井化学株式会社 2019-09-10 CN disclosed
EP-1599169-A4 METHOD FOR INCREASING HAIR GROWTH E L MANAGEMENT CORP (US) 2008-01-23 EP disclosed
CN-1852986-A Production of polyunsaturated fatty acids in oleaginous yeast DU PONT (US) 2006-10-25 CN disclosed
CN-1816559-A Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts DU PONT (US) 2006-08-09 CN disclosed
US-20050271739-A1 Methods and compositions for accelerating alcohol metabolism ENZYMEDIX 2005-12-08 US disclosed
EP-1599169-A2 METHOD FOR INCREASING HAIR GROWTH E-L Management Corp. (US) 2005-11-30 EP disclosed
WO-2004078117-A2 METHOD FOR INCREASING HAIR GROWTH E-L MANAGEMENT CORP. (US) 2004-09-16 WO disclosed
US-20040171693-A1 Method for increasing hair growth GAN DAVID C (US) 2004-09-02 US disclosed
EP-0973938-A4 THE USE OF NADPH AND NADH ANALOGS IN THE MEASUREMENT OF ENZYME ACTIVITIES AND METABOLITES SPECIALTY ASSAYS INC (US) 2000-04-26 EP disclosed
EP-0973938-A1 THE USE OF NADPH AND NADH ANALOGS IN THE MEASUREMENT OF ENZYME ACTIVITIES AND METABOLITES Specialty Assays, Inc. (US) 2000-01-26 EP disclosed
WO-1998033936-A1 THE USE OF NADPH AND NADH ANALOGS IN THE MEASUREMENT OF ENZYME ACTIVITIES AND METABOLITES SPECIALTY ASSAYS, INC. (US) 1998-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050271739-A1 Methods and compositions for accelerating alcohol metabolism ADH1A, ADH1C, ADH5 LDHA 285/4885SRR 594/4885OR51E2 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.